blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3122360

EP3122360 - PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR DIFFUSE LARGE B-CELL LYMPHOMA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.04.2021
Database last updated on 26.07.2024
FormerThe patent has been granted
Status updated on  15.05.2020
FormerGrant of patent is intended
Status updated on  30.01.2020
FormerExamination is in progress
Status updated on  23.11.2018
FormerRequest for examination was made
Status updated on  30.12.2016
FormerThe international publication has been made
Status updated on  31.10.2016
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
ONO Pharmaceutical Co., Ltd.
1-5, Doshomachi 2-chome Chuo-ku
Osaka-shi, Osaka 541-8526 / JP
[2017/05]
Inventor(s)01 / YOSHIZAWA, Toshio
c/o ONO PHARMACEUTICAL CO. LTD.
1-1 Sakurai 3-chome
Shimamoto-cho
Mishima-gun Osaka 618-8585 / JP
02 / KOZAKI, Ryohei
c/o ONO PHARMACEUTICAL CO. LTD.
1-1 Sakurai 3-chome
Shimamoto-cho
Mishima-gun Osaka 618-8585 / JP
 [2017/05]
Representative(s)Jones, Nicholas Andrew
Withers & Rogers LLP
2 London Bridge
London SE1 9RA / GB
[N/P]
Former [2017/05]Jones, Nicholas Andrew
Withers & Rogers LLP
4 More London Riverside
London, SE1 2AU / GB
Application number, filing date15768602.324.03.2015
[2017/05]
WO2015JP01676
Priority number, dateJP2014006141325.03.2014         Original published format: JP 2014061413
[2017/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015146159
Date:01.10.2015
Language:EN
[2015/39]
Type: A1 Application with search report 
No.:EP3122360
Date:01.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 01.10.2015 takes the place of the publication of the European patent application.
[2017/05]
Type: B1 Patent specification 
No.:EP3122360
Date:17.06.2020
Language:EN
[2020/25]
Search report(s)International search report - published on:JP01.10.2015
(Supplementary) European search report - dispatched on:EP14.08.2017
ClassificationIPC:A61K31/52, A61K35/12, A61K39/395, A61K45/00, A61P35/02, A61P43/00
[2017/05]
CPC:
A61K31/522 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP,US);
C07D473/34 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/05]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:PROPHYLAKTISCHER WIRKSTOFF UND/ODER THERAPEUTISCHER WIRKSTOFF FÜR DIFFUSES GROSSZELLIGES B-ZELL-LYMPHOM[2017/05]
English:PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR DIFFUSE LARGE B-CELL LYMPHOMA[2017/05]
French:AGENT PROPHYLACTIQUE ET/OU AGENT THÉRAPEUTIQUE POUR LYMPHOME DIFFUS À GRANDES CELLULES B[2017/05]
Entry into regional phase21.10.2016National basic fee paid 
21.10.2016Search fee paid 
21.10.2016Designation fee(s) paid 
21.10.2016Examination fee paid 
Examination procedure21.10.2016Examination requested  [2017/05]
21.10.2016Date on which the examining division has become responsible
16.02.2018Amendment by applicant (claims and/or description)
22.11.2018Despatch of a communication from the examining division (Time limit: M04)
22.03.2019Reply to a communication from the examining division
31.01.2020Communication of intention to grant the patent
05.05.2020Fee for grant paid
05.05.2020Fee for publishing/printing paid
05.05.2020Receipt of the translation of the claim(s)
Opposition(s)18.03.2021No opposition filed within time limit [2021/21]
Fees paidRenewal fee
09.03.2017Renewal fee patent year 03
12.03.2018Renewal fee patent year 04
11.03.2019Renewal fee patent year 05
12.03.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.03.2015
AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
MK17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
TR17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
[2024/29]
Former [2024/22]HU24.03.2015
AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
MK17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2023/30]HU24.03.2015
AL17.06.2020
AT17.06.2020
CY17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2023/27]HU24.03.2015
AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/45]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
MC17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/24]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SI17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/21]AL17.06.2020
AT17.06.2020
CZ17.06.2020
DK17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/10]AL17.06.2020
AT17.06.2020
CZ17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
PL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SK17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
IS17.10.2020
PT19.10.2020
Former [2021/09]AL17.06.2020
AT17.06.2020
CZ17.06.2020
EE17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
RO17.06.2020
RS17.06.2020
SE17.06.2020
SM17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
PT19.10.2020
Former [2021/04]AL17.06.2020
FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
NL17.06.2020
RS17.06.2020
SE17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
Former [2021/01]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
RS17.06.2020
SE17.06.2020
BG17.09.2020
NO17.09.2020
GR18.09.2020
Former [2020/51]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
RS17.06.2020
SE17.06.2020
NO17.09.2020
GR18.09.2020
Former [2020/50]FI17.06.2020
HR17.06.2020
LT17.06.2020
LV17.06.2020
SE17.06.2020
NO17.09.2020
GR18.09.2020
Former [2020/48]FI17.06.2020
LT17.06.2020
SE17.06.2020
NO17.09.2020
Former [2020/47]LT17.06.2020
NO17.09.2020
Documents cited:Search[XI]  - YASUHIRO TOMOKO ET AL, "ONO-4059, a novel oral Bruton's tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model", CANCER RESEARCH, & 103RD ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; CHICAGO, IL, USA; MARCH 31 -APRIL 04, 2012, (20130401), vol. 73, ISSN 0008-5472, XP009191992 [X] 1-8 * the whole document * [I] 9-11
International search[Y]WO2013081016  (ONO PHARMACEUTICAL CO [JP]) [Y] 1-11 * , Example 9, Biological Example 1, Paragraph[0039] & US 2014/0330015 A1 & EP 2786996 A1 & CN 103958513 A & KR 10-2014-0095516 A *;
 [Y]  - KOZAKI, R. et al., "Development of a Bruton's tyrosine kinase (Btk) inhibitor - ONO-WG-307, a potential treatment for B- cell malignancies", Cancer Research, (20120000), vol. 72, no. 8, XP 055225432 [Y] 1-11 * , Supp. SUPPL. 1, Abstract Number: 857 *
 [Y]  - DAVIS, R. E . et al., "Chronic active B- cell -receptor signalling in diffuse large B- cell lymphoma", Nature, (20100000), vol. 463, pages 88 - 92, XP 002646596 [Y] 3
 [A]  - SALLES, G. A. et al., "A phase I study of the oral btk inhibitor ONO-4059 in patients with relapsed/refractory and high risk Chronic Lymphocytic Leukaemia (CLL).", Blood, (20130000), vol. 122, no. 21, XP055369713 [A] 1-11 * , Abstract Number: 676 *
Examination   - NAYLOR TARA L ET AL, "Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas", CANCER RESEARCH, & 102ND ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); ORLANDO, FL, USA; APRIL 02 -06, 2011, vol. 71, no. 7, doi:10.1158/0008-5472.CAN-10-2525, ISSN 0008-5472, (20110401), pages 2643 - 2653, (20110215), XP008137907

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-10-2525
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.